Cargando…

Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma

SIMPLE SUMMARY: We investigated the prognosis of intermediate-stage hepatocellular carcinoma (HCC) patients who received lenvatinib (LEN) until unacceptable adverse events or progressive disease, followed by transcatheter arterial chemoembolization (TACE) on demand. The overall survival (OS) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mawatari, Seiichi, Tamai, Tsutomu, Kumagai, Kotaro, Saisyoji, Akiko, Muromachi, Kaori, Toyodome, Ai, Taniyama, Ohki, Sakae, Haruka, Ijuin, Sho, Tabu, Kazuaki, Oda, Kohei, Hiramine, Yasunari, Moriuchi, Akihiro, Sakurai, Kazuhiro, Kanmura, Shuji, Ido, Akio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776720/ https://www.ncbi.nlm.nih.gov/pubmed/36551623 http://dx.doi.org/10.3390/cancers14246139

Ejemplares similares

Serine palmitoyltransferase long chain subunit 3 is associated with hepatocellular carcinoma in patients with NAFLD
por: Ijuin, Sho, et al.
Publicado: (2022)

Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease
por: Tabu, Kazuaki, et al.
Publicado: (2021)

Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals
por: Tabu, Kazuaki, et al.
Publicado: (2020)

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus
por: Mawatari, Seiichi, et al.
Publicado: (2022)

Successful Percutaneous Transhepatic Obliteration Plus Sengstaken-Blakemore Tube Combination Therapy for Recurrent Gastroesophageal Variceal Bleeding
por: Toyodome, Ai, et al.
Publicado: (2022)

Glycoprotein non-metastatic melanoma protein B expression correlates with the prognosis of acute liver injury/failure
por: Kumagai, Kotaro, et al.
Publicado: (2023)

The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir
por: Mawatari, Seiichi, et al.
Publicado: (2018)

Human neutrophil peptide-1 promotes alcohol-induced hepatic fibrosis and hepatocyte apoptosis
por: Ibusuki, Rie, et al.
Publicado: (2017)

Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: A cross-sectional study
por: Kure, Takeshi, et al.
Publicado: (2019)

Glycoprotein Nonmetastatic Melanoma B (Gpnmb)-Positive Macrophages Contribute to the Balance between Fibrosis and Fibrolysis during the Repair of Acute Liver Injury in Mice
por: Kumagai, Kotaro, et al.
Publicado: (2015)

Hepatitis C Virus NS3/4A Protease Inhibits Complement Activation by Cleaving Complement Component 4
por: Mawatari, Seiichi, et al.
Publicado: (2013)

Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C
por: Mera, Kumiko, et al.
Publicado: (2014)

Extract of Lactobacillus plantarum strain 06CC2 induces JNK/p38 MAPK pathway-mediated apoptosis through endoplasmic reticulum stress in Caco2 colorectal cancer cells
por: Hiraishi, Nobuhiro, et al.
Publicado: (2019)

Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat
por: Kumamoto, Ryo, et al.
Publicado: (2013)

HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 Expression
por: Nishikoba, Nao, et al.
Publicado: (2020)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis
por: Kanmura, Shuji, et al.
Publicado: (2021)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma
por: Uchida‐Kobayashi, Sawako, et al.
Publicado: (2022)

Clinical Features of Hepatitis C Virus Carriers With Persistently Normal Alanine Aminotransferase Levels
por: Uto, Hirofumi, et al.
Publicado: (2012)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses
por: Tamai, Toshiyuki, et al.
Publicado: (2017)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Tachiiri, Tetsuya, et al.
Publicado: (2023)

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
por: Motzer, Robert J., et al.
Publicado: (2022)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
por: Liu, Juanfang, et al.
Publicado: (2021)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Curative surgery for multiple hepatocellular carcinomas after lenvatinib plus transarterial chemoembolization: a case report
por: Shiraishi, Jin, et al.
Publicado: (2023)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
por: He, Ying, et al.
Publicado: (2023)

Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Li, Dailong, et al.
Publicado: (2023)

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
por: Kuroda, Hidekatsu, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
por: Wu, Juan, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Cai, Mingyue, et al.
Publicado: (2022)

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023)

Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization
por: Shi, Qin, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f71o4uid35fac32huvjum8bkjn